Jpmorgan Chase & CO Galectin Therapeutics Inc Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 16,965 shares of GALT stock, worth $80,074. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,965
Previous 59,693
71.58%
Holding current value
$80,074
Previous $71,000
71.83%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding GALT
# of Institutions
94Shares Held
11.2MCall Options Held
134KPut Options Held
353K-
Vanguard Group Inc Valley Forge, PA2.18MShares$10.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$7.38 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.27MShares$5.97 Million0.01% of portfolio
-
Jane Street Group, LLC New York, NY749KShares$3.53 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA666KShares$3.14 Million0.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $280M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...